Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2009

01-04-2009 | Gastrointestinal Oncology

Challenges in Developing Robust Genetic Markers and Targets to Predict and Prevent Distant and Peritoneal Recurrence in Gastric Cancer

Authors: D. Ziogas, MD, D. H. Roukos, MD

Published in: Annals of Surgical Oncology | Issue 4/2009

Login to get access

Excerpt

Mimori et al. in a recent issue of the Journal reported interesting data on membrane type 1 matrix metalloproteinase (MT1-MMP) expression in peripheral blood and bone marrow of 810 patients with gastric cancer.1 This large-scale study evaluated the potential utility of MT1-MMP as a marker to predict risk of distant metastasis and peritoneal dissemination in gastric cancer. …
Literature
1.
Mimori K, Fukagawa T, Kosaka Y, Ishikawa K, Etoh T, Sasako M, et al. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oncol. 2008;15(10):2934–2942.PubMedCrossRef
2.
Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8(1):29–39.PubMedCrossRef
3.
Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15(4):956–60.PubMedCrossRef
4.
Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8(5):587–97.PubMedCrossRef
5.
Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn. 2009; 9(1):1–6.PubMedCrossRef
6.
Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, et al. Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature. 2007 Apr 12;446(7137):765–70.PubMedCrossRef
7.
Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. for Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.PubMedCrossRef
8.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRef
9.
Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2005;2:98–107.PubMedCrossRef
10.
Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9(9):828–30.PubMedCrossRef
11.
Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358(15):1636; author reply 1636.PubMed
12.
Vineis P, Brennan P, Canzian F, Ioannidis JPA, Matullo G, Ritchie M, et al. Expectations and challenges stemming from genome-wide association studies. Mutagenesis. 2008;23:439–44.PubMedCrossRef
13.
Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008;247(4):714–5.PubMedCrossRef
14.
15.
Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15(1):21–33.PubMedCrossRef
16.
Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197, author reply 198.PubMedCrossRef
17.
Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;118:1590–605.PubMedCrossRef
18.
Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 2008;26(26):4360–1.PubMedCrossRef
19.
Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2008 Aug 23. [Epub ahead of print] DOI: 10.​1245/​s10434-008-0109-6.
Metadata
Title
Challenges in Developing Robust Genetic Markers and Targets to Predict and Prevent Distant and Peritoneal Recurrence in Gastric Cancer
Authors
D. Ziogas, MD
D. H. Roukos, MD
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0300-9

Other articles of this Issue 4/2009

Annals of Surgical Oncology 4/2009 Go to the issue

ORIGINAL ARTICLE-THORACIC ONCOLOGY

Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center

Thoracic Oncology

Pulmonary Resection for Colorectal Cancer Metastases: Duration Between Cancer Onset and Lung Metastasis as an Important Prognostic Factor

Other

Lymph Node Yield as a Prognostic Factor in Cancer Studies—Due to Undersampling of Tumor-Free Lymph Nodes at Higher N Stages?

Melanomas

Optimizing Melphalan Pharmacokinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regional Response or Toxicity?

Breast Oncology

Men With Breast Cancer Have Same Disease-Specific and Event-Free Survival as Women

Breast Oncology

Endogenous NIS Expression in Triple-Negative Breast Cancers